Melanoma vaccine study pulled before starting
NCT ID NCT01861938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a special vaccine made from modified melanoma cells to help the immune system fight remaining cancer in people with high-risk or low-burden melanoma. It was designed for patients with certain genetic markers and stages of melanoma. However, the study was withdrawn before any participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a single eye injection shrink melanoma and save sight?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?